Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar 7;14(3):e15504.
doi: 10.15252/emmm.202115504. Epub 2022 Feb 2.

Can THEM6 targeting stop resistance to prostate cancer treatment?

Mrittika Chattopadhyay  1 , Doris Germain  1
Affiliations
Comment

Can THEM6 targeting stop resistance to prostate cancer treatment?

Mrittika Chattopadhyay et al. EMBO Mol Med. .

Abstract

Prostate cancer (PCa) clinical management relies heavily on androgen-deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non-resectable PCa eventually relapse and develop fatal castration-resistant PCa (CRPC). Multiple mechanisms of acquired resistance to treatment have been reported, including metabolic adaptation (Marine et al, 2020). Notably, activation of the endoplasmic reticulum (ER) unfolded protein response (UPR) has been associated with oncogenic transformation (Hart et al, 2012), tumor progression, metastasis dissemination, and resistance to therapy (Chen & Cubillos-Ruiz, 2021). Targeting different branches of ER UPR has been found to be an effective tool against aggressive PCa (Nguyen et al, 2018; Sheng et al, 2019). Therefore, a better understanding of these pathways may lead to the identification of novel drug targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
THEM‐6 in PCa cells is responsible for developing resistance to ADT by activating ER UPR and maintaining sterol biosynthesis.
See this image and copyright information in PMC

Comment on

  • THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.
    Blomme A, Peter C, Mui E, Rodriguez Blanco G, An N, Mason LM, Jamieson LE, McGregor GH, Lilla S, Ntala C, Patel R, Thiry M, Kung SHY, Leclercq M, Ford CA, Rushworth LK, McGarry DJ, Mason S, Repiscak P, Nixon C, Salji MJ, Markert E, MacKay GM, Kamphorst JJ, Graham D, Faulds K, Fazli L, Gleave ME, Avezov E, Edwards J, Yin H, Sumpton D, Blyth K, Close P, Murphy DJ, Zanivan S, Leung HY. Blomme A, et al. EMBO Mol Med. 2022 Mar 7;14(3):e14764. doi: 10.15252/emmm.202114764. Epub 2022 Jan 11. EMBO Mol Med. 2022. PMID: 35014179 Free PMC article.

References

    1. Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, Planque M, McGregor GH, Peixoto P, Hervouet E et al (2020) 2,4‐dienoyl‐CoA reductase regulates lipid homeostasis in treatment‐resistant prostate cancer. Nat Commun 11: 2508 - PMC - PubMed
    1. Blomme A, Peter C, Mui E, Blanco GR, An N, Mason LM, Jameison LE, MacGregor GH, Lilla S, Ntala C et al (2022) THEM‐6 mediated reprogramming of lipid metabolism supports treatment resistance in prostrate cancer. EMBO Mol Med 14: e14764 - PMC - PubMed
    1. Chen X, Cubillos‐Ruiz JR (2021) Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer 21: 71–88 - PMC - PubMed
    1. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu BO, Zhang H, Cerniglia G, Bi M et al (2012) ER stress‐mediated autophagy promotes Myc‐dependent transformation and tumor growth. J Clin Invest 122: 4621–4634 - PMC - PubMed
    1. Marine JC, Dawson SJ, Dawson MA (2020) Non‐genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer 20: 743–756 - PubMed

MeSH terms

Substances